Cite
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial
MLA
Murray, Miranda I., et al. Satisfaction and Acceptability of Cabotegravir Long-Acting Injectable Suspension for Prevention of HIV: Patient Perspectives from the ECLAIR Trial. Jan. 2018. EBSCOhost, https://doi.org/10.6084/m9.figshare.7356140.
APA
Murray, M. I., Markowitz, M., Frank, I., Grant, R. M., Mayer, K. H., Hudson, K. J., Stancil, B. S., Ford, S. L., Patel, P., Rinehart, A. R., Spreen, W. R., & Margolis, D. A. (2018). Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. https://doi.org/10.6084/m9.figshare.7356140
Chicago
Murray, Miranda I., Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Krischan J. Hudson, Britt S. Stancil, et al. 2018. “Satisfaction and Acceptability of Cabotegravir Long-Acting Injectable Suspension for Prevention of HIV: Patient Perspectives from the ECLAIR Trial,” January. doi:10.6084/m9.figshare.7356140.